Chairmen: Ian Stratford
Paul Workman
Norman Coleman

Ninth International Conference on
Chemical Modifiers of Cancer Treatment
August 22–26, 1995, Christ Church, Oxford, UK

In honour of: Gerald E. Adams
Norman M. Bleehan
Stanley Dische

ACKNOWLEDGEMENTS

Sponsors
- Cancer Research Campaign
- Sanofi Winthrop

Benefactors
- International Association for Radiation Research
- Associates of the Joint Center for Cancer Therapy (Boston)
- British Oncological Association
- US Bioscience
- Varian Associates
- United Kingdom Co-ordinating Committee for Cancer Research
- Eppendorf
- Warner-Lambert/Parke-Davis

Contributors
- Zeneca Pharmaceuticals
- Lilly Industries Limited
- IMPAC Medical Systems
- Oxford Optronix

With additional support from the Medical Research Council.
The British Journal of Cancer is published twice monthly on behalf of the Cancer Research Campaign by Stockton Press, a division of Macmillan Press Ltd.

Scope The British Journal of Cancer will consider papers which contain new information, constitute a distinct contribution to knowledge, and are relevant to the clinical, epidemiological, pathological or molecular aspects of oncology.

This journal is covered by Excerpta Medica, Current Advances in Genetics and Molecular Biology, Current Contents, Medline, Index Medicus, Index to Scientific Reviews and Science Citation Index.

Editorial Manuscripts (plus three copies) and all editorial correspondence should be sent to: Professor GE Adams, Editorial Office, British Journal of Cancer, MRC Radiobiology Unit, Chilton, Didcot, Oxfordshire OX11 0RD, UK.
Tel: +44 (0) 1235 832141. Fax: +44 (0) 1235 832142.

Advertisements Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex, CM6 1AP, UK.
Tel: +44 (0) 1371 874613. Fax: +44 (0) 1371 872273.

Publisher All business correspondence and reprint requests should be addressed to: British Journal of Cancer, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0) 1256 29242. Fax: +44 (0) 1256 810526.
Publisher: Jayne Marks
Production Controller: Debbie Cole
Supplement Editor: Alice Ellingham
Supplement Production Controller: Simone Larché

Subscriptions - EU/Rest of World Subscription price per annum (two volumes, 24 issues), EU £430, rest of the world £470 (surface), £560 (airmail), or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Magazines and sent to: The Subscription Department, Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire, RG21 6XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EU territories should add sales tax at the local rate.

Subscriptions - USA USA subscribers call toll free 1-800-221 2125 or send check/money order/credit card details to: Stockton Press, 345 Park Avenue South, 10th Floor, New York, NY 10010-1707. Tel: +1 212 689 9200. Fax: +1 212 689 9711. USA annual subscription rates (institutional/corporate): $745 (surface), $890 (airmail). Prices are set in UK Sterling. Dollar prices are converted to UK Sterling at the current exchange rate. Accord-ingly, your credit card charge may vary slightly from the dollar rate shown. To obtain the exact dollar rate shown above, please remit by check. All prices are subject to change without notice.

The British Journal of Cancer (ISSN 0007-0920) is published twice a month by Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is $890 per annum. 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA

Reprints of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0) 1256 29242. Fax: +44 (0) 1256 810526.

Copyright © 1996 Cancer Research Campaign
ISSN 0007-0920

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc, published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press, for libraries and other users registered with the Copyright Clearance Centre (CCC) Transaction Reporting Service, provided that the base fee of $12.00 per copy is paid directly to CCC, 21 Congress St, Salem, MA 01970, USA 0007-0920/96 $12.00 + $0.00

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency.

Typeset by Elite Typesetting Techniques, Eastleigh, Hants
Printed on acid-free paper, effective with Volume 69, Issue 1, 1994
Printed in Great Britain by Latimer Trend Company Ltd, Plymouth, Devon
FACULTY

Chairman
Ian J Stratford (UK)

Co-Chairmen
Paul Workman (UK)
Norman Coleman (USA)

Organising Committee
Alberto Breccia (Italy)
Martin Brown (USA)
Luciano Busutti (Italy)
Don Chapman (USA)
Tom Connors (UK)
Eric Hall (USA)
Ralph E Durand (Canada)
Tsutomu Kagiya (Japan)
Stan Kaye (UK)
Timothy Kinsella (USA)

Edmund Malaise (France)
James Mitchell (USA)
Jens Overgaard (Denmark)
Theodore Phillips (USA)
Garth Powis (USA)
Mike Rauth (Canada)
Dietmar Siemann (USA)
Yoshimasa Tanaka (Japan)
Robert Sutherland (USA)
Todd Wasserman (USA)
Gordon Whitmore (Canada)

Local Organising Committee
Dai Chaplin
Adrian Harris
Adrian Jones

George Radda
Peter Wardman

Honoured Guests
Gerald Adams
Norman Bleehen

Stanley Dische

Keynote Speakers
Gabi Dachs (UK)
Bill Denny (New Zealand)
John Griffiths (UK)
Ian Hickson (UK)
Lynn Hlatky (USA)

Paul Okunieff (USA)
David Ross (USA)
Michelle Saunders (UK)
Ken Tew (USA)

Young Investigator Awards
Christine Brezden (Canada)
David Cowan (New Zealand)
Sara Fitzsimmons (UK)
Ruth Langley (UK)
Carrie Peters (Canada)
Bronwyn Simm (USA)
Xiaoping Sun (PR China)
Ingunn Tufto (Norway)
Carolien Versantvoort (UK)
Bradley Wouters (Canada)
Message from the Chairmen

These proceedings provide a flavour of the 9th International Conference on Chemical Modifiers of Cancer Treatment. This meeting consisted of 196 oral contributions, including keynote talks, as well as 4 minute/4 slide presentations. This format has been a feature of the more recent Chemical Modifier meetings and the talks were accompanied by extended abstracts given to participants at the time of the meeting.

Presentations were representative of virtually all areas covered in previous Chemical Modifier meetings and indicated that the field is continuing to evolve. This is coming about, in part, by the application of new techniques derived from molecular biology. Thus, redox changes that occur in tumours (which previously have been considered major problems) are now recognised to cause substantial changes in cellular biochemistry. This better understanding of cell and tumour biology will provide new avenues for therapeutic exploitation.

The return of the Chemical Modifiers meeting to the UK coincides with the ‘retirement’ of three pioneers in the field, namely Professors Ged Adams, Norman Bleehen and Stanley Dische. It was they who organised the first Chemical Modifiers meeting in 1977, the proceedings of which were published in the British Journal of Cancer (38, suppl. III). Since then, these ‘pioneers’ have worked tirelessly in developing many of the concepts derived from, and included in, later meetings. Their work has set the highest standard and it is hoped that these proceedings provide a small tribute to these leaders, whose work one equates with scientific excellence.

Finally, the conference and the publication of these proceedings has been made possible by the tireless efforts of the secretarial team – Vikki Fielden and Jane McCourt at the MRC Harwell and Simone Larché at Stockton Press. Special thanks go to the Medical Research Council and, for generous major sponsorship, to the Cancer Research Campaign and the pharmaceutical company Sanofi Winthrop.

Science and the field of Chemical Modifiers moves on. The next meeting is in Florida, USA, in January 1998, chaired by Professor Dietmar Siemann. Enjoy these Proceedings and look forward to the next.

Ian Stratford, Paul Workman and Norman Coleman
(Co-Chairmen)
Author index to Supplement 27

Abe M S61
Abagyan EO S226
Abraham SK S102
Adams GE S177, S232
Adomat H S200
Anderson RF S48
Arnold S S164, S168, S260
Atkova G S282

Ballinger JR S264
Bandith JP S191
Barzilay S145
Batchelder RM S52
Beall HD S11
Begletcher A S9
Belej T S23
Bell KM S161
Bernhard E S140
Biaglow J S140
Biaglow JE S222
Bleehter NM S236
Bloomer WD S267
Bonner JA S109
Boyles DJ S78
Braun RD S241, S247
Braunfruit SJ S157
Brezen CB S19
Briggs LA S15
Brizel DM S241
Broadhurst S S99
Budd R S99
Bump EA S117, S157

Cerveny C S78
Chadwick JA S75
Chaplin DJ S75, S86, S122, S133, S161, S164, S168, S260
Chapman JD S204, S209
Chin L S78
Chou SC S213
Christodoulou D S181
Ciaccio PJ S93
Coia LR S204
Coleman CN S117, S151, S297
Collingridge D S168
Cook JA S181
Cornwell MM S78
Cowan DCM S28, S264
Curphey TJ S9

D’Abrav S S99
Dachs GU S126
de Bie J S185
De Graff W S181
Delfs JR S117
Dennis MF S70, S172

Denny WA S32, S43, S48, S52
Dewhirst MW S241, S247
Ding I S105
Dische S S271
Dobrowsky E S279
Dobrowsky W S279
Dunphy EP S185
Engelhardt EL S204
Everett SA S70, S172
Freiler N S200
Fenning MC S204
Finger VH S89
Fisher J S181
Flood PM S213
Fowler JP S294
Fryer OP S39
Fryer CJH S122

Gamson J S181
Geuca C S117
Goodman GB S122
Grasal M S279
Griffith RJ S217
Griffiths JR S226
Gustafson DL S1

Hahnfeldt P S151
Halinska A S23
Hall EJ S57
Hay MP S32, S52
Hei TK S57
Hejmassi MV S39
Hicks KO S28
Hickson JD S145
Hill SA S86, S168, S260
Hiroaka M S61, S114
Hirohashi M S114
Hirst DG S39
Hlatky L S151
Hoeckel M S185
Hofstrand P S78
Honeck DJ S236
Hong K S247
Horsman MR S168, S232
Hoskin PJ S260
Huang K S105
Hurl W-J S217
Hurwitz SJ S117

Inomata T S122
Iwata K S217
Jackson SM S191
Ji M S267
Johnsen NM S136
Kauzty M S279
Kelly DP S99
Kesavan PC S102
Kim S S222
Kimura H S247
King P S200
Kinsella TJ S294
Kitamoto Y S236
Koch C S200
Kohler W S279
Krishna MC S181
Kuehl BL S19

Lai L S157
Lam GYK S122
Lamppu DM S82
Le Riçek J S191
Leacy M S260
Lee HH S43
Leith MK S9
Li AE S43
Lindberg RD S89
Liu SX S57
Lord E S200
Lyng H S136, S252
McGuick CL S226
McCaw AG S209
McIntyre DJO S226
McIntyre IA S39
McKenna WG S140
McKeown SN S39
Makepeace CM S217
Manevich Y S222
Mannan RH S209
Martin RF S99
Matthews J S200
Maurer BJ S78
Maxwell RJ S232
Medeiros D S157
Melo T S264
Menton-Brennan L S117
Mercer JR S209
Millesi W S279
Mitchell JB S181
Miyauchu S S114
Morin C S209
Murata R S61, S114
Muschel R S140

Nabout J S279
Naylor MA S70
Nishioka A S122
Nordmark M S232
O’Bein P S260
O’Brien PJ S23, S287
Ogawa Y S122

Okkan S S282
Okumieff P S105, S185
Olive PL S191
Ong ET S241
Overgaard J S168, S232
Oya N S61, S114

Palayoor RT S117
Palcic B S122, S200
Papadopoulos MV S267
Papahadjopoulos D S247
Park L S264
Parkins CS S75
Parliament MB S209
Patel KB S70, S172
Patterson LH S39, S43
Pavelka R S279
Pavlou M S222
Pettiti GR S86
Pigott KH S260
Poulin N S200
Powell MEB S260
Prise VE S161
Pritsos CA S15
Priyadarshini KI S70
Pulley SM S43

Radacic M S168
Raleigh JA S213
Rampling MR S236
Rasey JS S78
Rauth AM S19, S264
Rehmus SW S241
Rehmus SWE S247
Reichel M S279
Renzing J S19
Reum M S99
Robinson SP S226
Rofstad EK S136, S252
Rosner GL S241
Ross D S1, S19
Rothwell DG S145

Sahinler I S282
Sampson LE S133
Sangulin J S200
Sansom JM S177
Saroff DM S117
Sasai K S61, S114
Saunders M S271
Saunders MI S260
Sawyer TE S109
Schneider RF S204
Secomb TW S241, S247
Sehphon R S99
Shakil A S217
Shan S S241
Shibamoto Y S61, S114
<table>
<thead>
<tr>
<th>Author</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shibata</td>
<td>S61</td>
</tr>
<tr>
<td>Siegel</td>
<td>S1, S19</td>
</tr>
<tr>
<td>Siemann</td>
<td>S65</td>
</tr>
<tr>
<td>Sigdestad</td>
<td>S89</td>
</tr>
<tr>
<td>Singh</td>
<td>S102</td>
</tr>
<tr>
<td>Skov</td>
<td>S200</td>
</tr>
<tr>
<td>Smith</td>
<td>S172</td>
</tr>
<tr>
<td>Song</td>
<td>S217</td>
</tr>
<tr>
<td>Sood</td>
<td>S287</td>
</tr>
<tr>
<td>Stevenson</td>
<td>S117</td>
</tr>
<tr>
<td>Stobbe</td>
<td>S204</td>
</tr>
<tr>
<td>Stratford</td>
<td>S70, S126, S177, S232</td>
</tr>
<tr>
<td>Stratford</td>
<td>MRL S70, S172</td>
</tr>
<tr>
<td>Szabo</td>
<td>S177</td>
</tr>
<tr>
<td>Takagi</td>
<td>T S61, S114</td>
</tr>
<tr>
<td>Takahashi</td>
<td>M S61</td>
</tr>
<tr>
<td>Terris</td>
<td>DJ S185</td>
</tr>
<tr>
<td>Tew</td>
<td>KD S93</td>
</tr>
<tr>
<td>Thiemermann</td>
<td>C S177</td>
</tr>
<tr>
<td>Thompson</td>
<td>KM S43</td>
</tr>
<tr>
<td>Tishler</td>
<td>RB S82</td>
</tr>
<tr>
<td>Tozer</td>
<td>GM S161</td>
</tr>
<tr>
<td>Tracy</td>
<td>M S70</td>
</tr>
<tr>
<td>Traver</td>
<td>RD S1, S19</td>
</tr>
<tr>
<td>Trotter</td>
<td>T S191</td>
</tr>
<tr>
<td>Tsionou</td>
<td>C S151</td>
</tr>
<tr>
<td>Tufto</td>
<td>I S252</td>
</tr>
<tr>
<td>Turkan</td>
<td>S282</td>
</tr>
<tr>
<td>Tuttle</td>
<td>S140</td>
</tr>
<tr>
<td>Urtasun</td>
<td>RC S209</td>
</tr>
<tr>
<td>Uzel</td>
<td>R S282</td>
</tr>
<tr>
<td>Vane</td>
<td>JR S177</td>
</tr>
<tr>
<td>Vojnovic</td>
<td>B S256</td>
</tr>
<tr>
<td>Walker</td>
<td>LJ S145</td>
</tr>
<tr>
<td>Ward</td>
<td>G S260</td>
</tr>
<tr>
<td>Wardman</td>
<td>P S70, S172, S256</td>
</tr>
<tr>
<td>Ware</td>
<td>DC S48</td>
</tr>
<tr>
<td>Watts</td>
<td>ME S164</td>
</tr>
<tr>
<td>Wheeler</td>
<td>KT S196</td>
</tr>
<tr>
<td>Wiebe</td>
<td>LI S209</td>
</tr>
<tr>
<td>Wieman</td>
<td>TJ S89</td>
</tr>
<tr>
<td>Wilson</td>
<td>GD S279</td>
</tr>
<tr>
<td>Wilson</td>
<td>WR S28, S32, S43, S48, S52</td>
</tr>
<tr>
<td>Wink</td>
<td>DA S181</td>
</tr>
<tr>
<td>Wood</td>
<td>PJ S168, S177, S232</td>
</tr>
<tr>
<td>Wroblewski</td>
<td>K S222</td>
</tr>
<tr>
<td>Wu</td>
<td>T S105</td>
</tr>
<tr>
<td>Young</td>
<td>WK S256</td>
</tr>
<tr>
<td>Zhang</td>
<td>H S196</td>
</tr>
</tbody>
</table>
Subject index to Supplement 27

Acridine S28, S267
Actin filaments S157
ADEPT S32
Amiloride S75
Apoptosis S145, S172
AQ4N S39, S43
Artificial antigens S213
ATP S15
Bioreductive antitumour agents S9
Bioreductive drugs S15, S43, S48, S57, S65, S209
Bloodflow S86
BMS181321 S264
BOF-A2 S114
Bone marrow S105
Bone marrow toxicity S65
BSO S93
BuDR S294
Camptothecin S109
Carbogen S241
Carbon spin resonance S226
Cardiotoxicity S15
Cell contact S78
Cell cycle distribution S109
Cervix S282
CHART S271, S279
Chlorambucil S75
Chloroethanol S287
Clastogenic mechanism S52
CNDP S114
Combination chemotherapy S65
Combretastatin S86
Comet assay S191
Cytokines S105, S133
Cytokinesis-block micronucleus assay S61
Cytotoxicity S23, S172
clastogenic mechanism of S52
hypoxia selective S48
Cytotoxins, radiation activated S32
3-D cell growth S78
DACA S43
Dihydrolipoyl dehydrogenase S93
1,2-Dithiole-3-thione S9
DMXAA S43
DNA damage S145
DNA repair S145
DNA strand breaks S196
DNA targeting S200
DNA–protein cross links S196
Actinin S86
Drug resistance S264
DT-diaphorase S1, S9, S19, S23, S93
E09 S1, S9
Endothelial cells S151
human umbilical vein S164
Endothelin A receptors S161
Endothelin B receptors S161
Endothelin-1 S161
Energy metabolism S232
Eppendorf oxygen electrode S168
EPR spectroscopy S172
Erythrocyte flux S260
Erythropoietin S126
Ethacrynic acid S93
FAA S86
Garlic S102
GDEPT S32
Gene expression S151
Gene therapy S126
9L glioma S222
Glucose S222
α-Glutamylcysteine synthetase S93
Glutathione depletion S109
Glutathione S-transferase S102
HAP1 S145
Heterocyclic N-oxide S57
Hoechst 33342 S99
HT29 tumour S260
Human leucocyte filterability S236
Hydrogen abstraction S70
Hydroperoxide S140
Hydroxyguanidine S172
Hyperoxia S241
Hyperthermia S168
acute S236
human tumour S191
Hypoxia inducible factor 1 S126
Hypoxia markers S213
Hypoxic cells S264
Hypoxic toxicity S57
Ilosfamide S287
Image cytometry S200
Imaging S209
Interstitial fluid pressure S252
Intracellular pH S75
Iodoazomycin arabinoside S204, S209
β-iodoazomycin xylopyranoside S204
IUdR S294
Ketamine S222
KU-285 S61
Labelling indices S294
Lactate S226
Laser Doppler flowmetry S168
Lymphoblasts S23
Magnetic resonance spectroscopy S226
MDA-MB-231 cells S164
Melanomas S136
Melanoma xenografts S252
Metastases S122
Microcirculation S157
Micronucleus formation S52
Micronucleus test S102
Minor groove binding S99
Misonidazole S28
Mitochondrial DNA S15
Mitomycin C S1, S9, S19, S279
Monolayers S78
myc S140
Myoglobin S226
Neoacarnosinostatin S52
Neurotoxicity S117
Nicotinamide S236, S271
Nigericin S75
Nitric oxide S172, S177, S181
Nitro-arginine S168
Nitroimidazoles S200, S209, S213, S267
Nitroimidazoles probes S226
Nitroxide S157
NLA-1 S267
NLP-1 S267
NQO1 S1
Oncogenicity S57
One-electron reduction S48, S57
Oxidazole S282
N-Oxides S70
Oxygen electrodes S217
Oxygen enhancement ratio S122
Oxygen tension S252
Oxygenation S185
p21 S82
p53 S82
P450 S287
P450 reductase S1, S19
Pentose cycle S140
Pentoxifylline S236
Perfluorocarbon S226
Perfusion S241
Perfusion rate S252
pH glycolysis S222
Phenanthridine S28
Photofrin S89
Pimozidazole S28
Potential tumour cell doubling time S279
Proamine S99
Pulse radiolysis S172
Quinones S23
Radiation S39, S61, S82, S114, S122, S181
Radiation effects S105
Radiation protective agents S89
Radiation response S78
Radiation sensitivity S19, S247
Radicals S70
Radioprotection S102
Radiosensitisers S117, S271, S282
Radiotherapy S271, S282
Rate constants S70
RB6145 S168
RB90740 S70
RE90740 S57
Red cell flux S247
Relative biological effective-ness S122
Reoxygenation S191
Repopulation S279
S-phase sensitisers S294
SaF murine tumour S260
Sarafotoxin S6c S161
SCCCVII mouse tumour S114
Sensitisation S181
Sensitiser enhancement ratio S294
Single photon emission computerised tomography S204
Spheroids S78
SR-2508 S267
<table>
<thead>
<tr>
<th>Subject</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulphydryl depletion</td>
<td>S117</td>
</tr>
<tr>
<td>Superoxides</td>
<td>S157</td>
</tr>
<tr>
<td>Suppressor genes</td>
<td>S136</td>
</tr>
<tr>
<td>T.199</td>
<td>S93</td>
</tr>
<tr>
<td>Taxol</td>
<td>S82</td>
</tr>
<tr>
<td>Tetraploidisation</td>
<td>S136</td>
</tr>
<tr>
<td>Therapeutic gain</td>
<td>S39</td>
</tr>
<tr>
<td>THNLA-1</td>
<td>S267</td>
</tr>
<tr>
<td>Time-resolved fluorescence</td>
<td>S256</td>
</tr>
<tr>
<td>Tirapazamine</td>
<td>S1, S39, S61, S70, S86</td>
</tr>
<tr>
<td>TNFα, see Tumour necrosis factor α</td>
<td>S133</td>
</tr>
<tr>
<td>Topoisomerase inhibitors</td>
<td>S43</td>
</tr>
<tr>
<td>Total body irradiation</td>
<td>S105</td>
</tr>
<tr>
<td>Transcription factors</td>
<td>S145</td>
</tr>
<tr>
<td>Tumours, human</td>
<td>S185</td>
</tr>
<tr>
<td>Tumour blood flow</td>
<td>S161</td>
</tr>
<tr>
<td>Tumour control probability</td>
<td>S185</td>
</tr>
<tr>
<td>Tumour imaging</td>
<td>S264</td>
</tr>
<tr>
<td>Tumour microenvironment</td>
<td>S133, S164</td>
</tr>
<tr>
<td>U937 cells</td>
<td>S133</td>
</tr>
<tr>
<td>V79 cells</td>
<td>S109</td>
</tr>
<tr>
<td>Vascular resistance</td>
<td>S161</td>
</tr>
<tr>
<td>Vascular tone</td>
<td>S177</td>
</tr>
<tr>
<td>Vasoactive agents</td>
<td>S232, S241</td>
</tr>
<tr>
<td>Vinblastine</td>
<td>S75, S82, S86</td>
</tr>
<tr>
<td>Wound healing</td>
<td>S151</td>
</tr>
<tr>
<td>WR-2721</td>
<td>S89</td>
</tr>
<tr>
<td>WR-3689</td>
<td>S89</td>
</tr>
<tr>
<td>Xanthine oxidase</td>
<td>S1</td>
</tr>
<tr>
<td>Xylazine</td>
<td>S222</td>
</tr>
</tbody>
</table>